Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;49(2):783-785.
doi: 10.1007/s00259-021-05543-5. Epub 2021 Sep 8.

[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma

Simone Krebs  1   2 , Christian Grommes  3 , Michael R McDevitt  1   2 , Sean D Carlin  4 , Joseph A O'Donoghue  5 , Maya S Graham  3 , Robert J Young  6 , Heiko Schöder  1   2 , Philip H Gutin  7 , Neil H Bander  8 , Joseph R Osborne  9   10
Affiliations

[89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma

Simone Krebs et al. Eur J Nucl Med Mol Imaging. 2022 Jan.

Erratum in

No abstract available

PubMed Disclaimer

References

    1. Pandit-Taskar N, O’Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gonen M, Lewis JS, Holland JP, Cheal SM, Reuter VE, Osborne JR, Loda MF, Smith-Jones PM, Weber WA, Bander NH, Scher HI, Morris MJ, Larson SM. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(11):2093–105. https://doi.org/10.1007/s00259-014-2830-7 . - DOI - PubMed - PMC
    1. Pandit-Taskar N, O’Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AM, Solomon SB, Gönen M, Heller G, Loda M, Nanus DM, Tagawa ST, Feldman JL, Osborne JR, Lewis JS, Reuter VE, Weber WA, Bander NH, Scher HI, Larson SM, Morris MJ. A phase I/II study for analytic validation of 89Zr-J591 immunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res. 2015;21(23):5277–85. https://doi.org/10.1158/1078-0432.Ccr-15-0552 . - DOI - PubMed - PMC
    1. Wernicke AG, Edgar MA, Lavi E, Liu H, Salerno P, Bander NH, Gutin PH. Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med. 2011;135(11):1486–9. https://doi.org/10.5858/arpa.2010-0740-OA . - DOI - PubMed
    1. Saffar H, Noohi M, Tavangar SM, Saffar H, Azimi S. Expression of prostate-specific membrane antigen (PSMA) in brain glioma and its correlation with tumor grade. Iran J Pathol. 2018;13(1):45–53. - DOI
    1. Holzgreve A, Biczok A, Ruf VC, Liesche-Starnecker F, Steiger K, Kirchner MA, Unterrainer M, Mittlmeier L, Herms J, Schlegel J, Bartenstein P, Tonn JC, Albert NL, Suchorska B. PSMA expression in glioblastoma as a basis for theranostic approaches: a retrospective, correlational panel study including immunohistochemistry, clinical parameters and PET imaging. Front Oncol. 2021;11: 646387. https://doi.org/10.3389/fonc.2021.646387 . - DOI - PubMed - PMC

LinkOut - more resources